Business
Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ
The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials NEW YORK, June 9, 2022 /PRNewswire/ -- Hoth
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials\nNEW YORK, June 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into an extension of its Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of Alzheimer's disease.\n\n \n \n \n \n \n \n\n \nThe research will continue to be led by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine. Based on the data generated from the first set of Alzheimer mouse model studies, Hoth plans to continue investigating the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease. The goal of these additional studies is to determine if HT-ALZ can improve learning and memory in an APP/PS1 mouse model of Alzheimer's disease after chronic administration prior to performing behavioral tests. The chronic dosing studies will also include a broad range of HT-ALZ doses to determine if there are dose-dependent effects on behavioral outcomes. The outcome of these studies is to estimate a human equivalent dose for initiating clinical trials for HT-ALZ.\nAD is a neurodegenerative disease that is characterized by aggregates of amyloid β (Aβ) plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical symptoms of the disease such as dementia. The initial experiments, conducted by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine, focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aβ in the brain interstitial fluid, using an established Alzheimer's Disease mouse model (aged APP/PS1+/- mice). The initial data from these studies showed a significant decrease in Aβ in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels, supporting that HT-ALZ has the potential to modify Aβ plaque formation in the brain and be developed as an AD therapeutic.\nAbout Hoth Therapeuti...